USANA Health Sciences, Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $10.8M | $42.0M | $63.8M | $69.4M | $124.7M | $100.5M | $126.2M | $62.5M |
| Depreciation & Amortization | $32.6M | $14.5M | $12.7M | $13.4M | $13.7M | $14.7M | $16.8M | $16.1M |
| Depreciation | $13.8M | $13.2M | $10.9M | $11.4M | $12.2M | $13.1M | $15.2M | $14.5M |
| Amortization | $19.3M | $1.5M | $1.8M | $1.7M | $1.3M | $1.4M | $1.5M | $1.5M |
| Stock-Based Compensation | $13.8M | $14.6M | $14.6M | $13.3M | $14.4M | $15.5M | $15.0M | $15.5M |
| Net Cash from Operating Activities | $22.3M | $61.0M | $70.6M | $103.9M | $160.4M | $126.7M | $152.1M | $123.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $13.8M | $10.1M | $14.5M | $10.4M | $15.1M | $16.6M | $11.4M | $13.2M |
| Business Acquisitions | $0 | $203.3M | $0 | $6.5M | $0 | — | — | — |
| Net Cash from Investing Activities | $-10.1M | $-213.1M | $-12.0M | $-12.4M | $-34.0M | $47.5M | $-69.0M | $-12.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $27.5M | $9.4M | $11.6M | $25.4M | $57.0M | $150.0M | $105.4M | $50.0M |
| Net Cash from Financing Activities | $-40.6M | $9.6M | $-14.2M | $-30.1M | $-59.4M | $-152.1M | $-105.3M | $-50.3M |
| Net Change in Cash | $-23.3M | $-148.7M | $41.9M | $47.7M | $78.2M | $20.5M | $-33.3M | $71.4M |
| Free Cash Flow | $8.5M | $50.9M | $56.1M | $93.5M | $145.3M | $110.2M | $140.7M | $110.6M |